Immunovant, Inc. (IMVT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US45258J1025
Immunovant, Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| EBIT | -412.95 m USD | -505.39 m USD |
| Net income | -413.84 m USD | -505.61 m USD |
| Diluted EPS – continuing operations | -2.73 USD | -2.77 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
More stocks
- Caesars Entertainment, Inc. (CZR)
- Wuhan Jingce Electronic Technology Co Ltd (300567.SZ)
- LEAR CORP (LEA)
- Essent Group Ltd. (ESNT)
- CASELLA WASTE SYSTEMS INC (CWST)
- BLACK HILLS CORP /SD/ (BKH)
- Silergy Corp (6415.TW)
- Hanjinkal (180640.KS)
- Suzhou Maxwell Technologies Co Ltd Class A (300751.SZ)
- Emmi AG (EMMN.SW)
- CSSC Offshore & Marine Engineering Group Co Ltd (600685.SS)
- T&S Communications Co Ltd (300570.SZ)
Not investment advice. All data without warranty, price as of 20.10.2026. Details in the risk notice.